These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 36016407)

  • 21. Th1 memory differentiates recombinant from live herpes zoster vaccines.
    Levin MJ; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Weinberg A
    J Clin Invest; 2018 Oct; 128(10):4429-4440. PubMed ID: 30024861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The herpes zoster subunit vaccine.
    Cunningham AL
    Expert Opin Biol Ther; 2016; 16(2):265-71. PubMed ID: 26865048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abortive intrabronchial infection of rhesus macaques with varicella-zoster virus provides partial protection against simian varicella virus challenge.
    Meyer C; Engelmann F; Arnold N; Krah DL; ter Meulen J; Haberthur K; Dewane J; Messaoudi I
    J Virol; 2015 Feb; 89(3):1781-93. PubMed ID: 25410871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine profile of herpes zoster (HZ/su) subunit vaccine.
    Cunningham AL; Heineman T
    Expert Rev Vaccines; 2017 Jul; 16(7):1-10. PubMed ID: 28486850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine.
    Fochesato M; Dendouga N; Boxus M
    Hum Vaccin Immunother; 2016 Aug; 12(8):2092-2095. PubMed ID: 26933767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.
    Chlibek R; Bayas JM; Collins H; de la Pinta ML; Ledent E; Mols JF; Heineman TC
    J Infect Dis; 2013 Dec; 208(12):1953-61. PubMed ID: 23904292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VZV T cell-mediated immunity.
    Weinberg A; Levin MJ
    Curr Top Microbiol Immunol; 2010; 342():341-57. PubMed ID: 20473790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation.
    Jacquet A; Haumont M; Massaer M; Garcia L; Mazzu P; Daminet V; Grégoire D; Jacobs P; Bollen A
    Vaccine; 2002 Feb; 20(11-12):1593-602. PubMed ID: 11858867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
    Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baculovirus Vector-Based Varicella-Zoster Virus Vaccine as a Promising Alternative with Enhanced Safety and Therapeutic Functions.
    Lee C; Kim M; Chun J; Kim S; Yoon D; Lee H; Bang H; Lee HJ; Park H; Kim YB
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Synergistic Lipid Nanoparticle Encapsulating mRNA Shingles Vaccine Induces Potent Immune Responses and Protects Guinea Pigs from Viral Challenges.
    Cheng X; Liu S; Sun J; Liu L; Ma X; Li J; Fan B; Yang C; Zhao Y; Liu S; Wen Y; Li W; Sun S; Mi S; Huo H; Miao L; Pan H; Cui X; Lin J; Lu X
    Adv Mater; 2024 Mar; 36(13):e2310886. PubMed ID: 38145557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipo-pam™ adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responses.
    Jeong SK; Ham SJ; Baek SH; Jung EJ; Jo HJ; Cha HR; Lee JM; Ahn BC; Yum JS; Chun E
    NPJ Vaccines; 2024 Aug; 9(1):150. PubMed ID: 39154056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster.
    Ulaszewska M; Merelie S; Sebastian S; Lambe T
    Hum Vaccin Immunother; 2023 Dec; 19(1):2175558. PubMed ID: 36785938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of Varicella-Zoster Virus-Specific Plasma Cells in Adult Human Bone Marrow following Childhood Vaccination.
    Eberhardt CS; Wieland A; Nasti TH; Grifoni A; Wilson E; Schmid DS; Pulendran B; Sette A; Waller EK; Rouphael N; Ahmed R
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32321817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
    Lasagna A; Mele D; Bergami F; Alaimo D; Dauccia C; Alessio N; Comolli G; Pasi F; Muzzi A; Novelli V; Baldanti F; Pedrazzoli P; Cassaniti I
    Hum Vaccin Immunother; 2023 Dec; 19(3):2288282. PubMed ID: 38037900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Herpes Zoster Vaccine].
    Watanabe D
    Uirusu; 2018; 68(1):21-30. PubMed ID: 31105132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques.
    Huang L; Zhao T; Zhao W; Shao A; Zhao H; Ma W; Gong Y; Zeng X; Weng C; Bu L; Di Z; Sun S; Dai Q; Sun M; Wang L; Liu Z; Shi L; Hu J; Fang S; Zhang C; Zhang J; Wang G; Loré K; Yang Y; Lin A
    Emerg Microbes Infect; 2024 Dec; 13(1):2309985. PubMed ID: 38258878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine.
    Luan N; Cao H; Wang Y; Lin K; Liu C
    Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.